Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma
{{output}}
Background: Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia. P... ...
